NZ523606A - Pharmaceutical compositions and methods for use - Google Patents

Pharmaceutical compositions and methods for use

Info

Publication number
NZ523606A
NZ523606A NZ523606A NZ52360601A NZ523606A NZ 523606 A NZ523606 A NZ 523606A NZ 523606 A NZ523606 A NZ 523606A NZ 52360601 A NZ52360601 A NZ 52360601A NZ 523606 A NZ523606 A NZ 523606A
Authority
NZ
New Zealand
Prior art keywords
methods
pharmaceutical compositions
composition
compound
formula
Prior art date
Application number
NZ523606A
Other languages
English (en)
Inventor
Gary Maurice Dull
Jean-Pierre Leconte
Humayun Kabir
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NZ523606A publication Critical patent/NZ523606A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ523606A 2000-07-14 2001-07-11 Pharmaceutical compositions and methods for use NZ523606A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,743 US6432954B1 (en) 2000-07-14 2000-07-14 Pharmaceutical compositions and methods for use
PCT/US2001/021872 WO2002005798A2 (en) 2000-07-14 2001-07-11 Pharmaceutical compositions for treating neurological disorders

Publications (1)

Publication Number Publication Date
NZ523606A true NZ523606A (en) 2004-12-24

Family

ID=24470778

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ523606A NZ523606A (en) 2000-07-14 2001-07-11 Pharmaceutical compositions and methods for use

Country Status (16)

Country Link
US (1) US6432954B1 (cg-RX-API-DMAC7.html)
EP (1) EP1311265B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004509851A (cg-RX-API-DMAC7.html)
CN (2) CN1680326A (cg-RX-API-DMAC7.html)
AT (1) ATE285773T1 (cg-RX-API-DMAC7.html)
AU (2) AU2290902A (cg-RX-API-DMAC7.html)
BR (1) BR0112130A (cg-RX-API-DMAC7.html)
CA (1) CA2415901A1 (cg-RX-API-DMAC7.html)
DE (1) DE60108130T2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301553A3 (cg-RX-API-DMAC7.html)
IL (3) IL153577A0 (cg-RX-API-DMAC7.html)
NO (1) NO20030155L (cg-RX-API-DMAC7.html)
NZ (1) NZ523606A (cg-RX-API-DMAC7.html)
PL (1) PL360532A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002005798A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300135B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20070219238A1 (en) * 2004-04-21 2007-09-20 Basf Aktiengesellschaft Fungicidal Mixtures
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2133337A1 (en) * 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
WO2008034041A2 (en) * 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CA2695214A1 (en) * 2007-07-31 2009-02-05 Targacept, Inc. Transdermal administration of (2s)-(4e)-n-methyl-5-(3-(5-is0pr0p0xypyridin)yl)-4-penten-2-amine
AU2011256866B2 (en) 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409551A (en) 1972-04-14 1975-10-08 Allen & Hanburys Ltd Cyclopent a indene derivatives
US4528290A (en) 1984-01-30 1985-07-09 Eli Lilly And Company Stimulating dopamine D-1 receptors
GB8606254D0 (en) 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
FR2664600B1 (fr) 1990-07-16 1994-09-02 Rhone Poulenc Sante Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib.
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
WO1996008468A1 (en) * 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
JP3603177B2 (ja) * 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
DK1086082T3 (da) * 1998-06-16 2004-11-22 Targacept Inc Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister
DE10032456A1 (de) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use

Also Published As

Publication number Publication date
DE60108130D1 (de) 2005-02-03
ATE285773T1 (de) 2005-01-15
IL192287A0 (en) 2008-12-29
HUP0301553A3 (en) 2005-05-30
WO2002005798A2 (en) 2002-01-24
NO20030155D0 (no) 2003-01-13
CA2415901A1 (en) 2002-01-24
HUP0301553A2 (hu) 2003-08-28
EP1311265A2 (en) 2003-05-21
CN1468100A (zh) 2004-01-14
EP1311265B1 (en) 2004-12-29
AU2002222909B2 (en) 2005-12-15
NO20030155L (no) 2003-03-13
CN1680326A (zh) 2005-10-12
IL153577A0 (en) 2003-07-06
JP2004509851A (ja) 2004-04-02
ZA200300135B (en) 2004-04-06
IL153577A (en) 2009-07-20
DE60108130T2 (de) 2006-02-23
WO2002005798A3 (en) 2003-03-13
AU2290902A (en) 2002-01-30
US6432954B1 (en) 2002-08-13
BR0112130A (pt) 2003-09-02
PL360532A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
IL153297A0 (en) Compounds and compositions for delivering active agents
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
UA94901C2 (ru) Антибактериальные производные пиперидина
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
NZ523606A (en) Pharmaceutical compositions and methods for use
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
WO2001095890A3 (en) Oral pharmaceutical compositions containing terbinafine
MXPA05005919A (es) Composiciones de ifosfamida para la administracion parenteral, y un proceso para su preparacion.
IL140839A0 (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis
CZ176395A3 (en) The use of riluzol for preparing medicaments acceptable as antidotes against harmful effects of irradiation

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: TARGACEPT, US

Free format text: OLD OWNER(S): AVENTIS PHARMA S.A.; TARGACEPT, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)